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Abstract
There is progressive concern about the evolving burden of morbidity and mortality caused
by coinfection with HIV-1 and hepatitis B virus (HBV) in sub-Saharan Africa, but the epide-
miology and impact of this problem are not well defined. We therefore set out to assimilate
more information about the nature of HBV/HIV coinfection in this region by undertaking a
retrospective observational study of southern African adult women. We used samples from
previously recruited HIV-1 positive women attending antenatal clinics in three settings in
South Africa and Botswana (n = 950) and added a small cohort of HIV-negative antenatal
South African women for comparison (n = 72). We tested for HBsAg and followed up
HBsAg-positive samples by testing for HBeAg, HBV DNA, HBV genotype, presence of
drug-resistance associated mutations (RAMs) and HDV. We identified HBsAg in 72 individ-
uals (7% of the whole cohort), of whom 27% were HBeAg-positive, and the majority HBV
genotypes A1 and A2. We did not detect any HDV coinfection. HBV prevalence was signifi-
cantly different between geographically distinct cohorts, but did not differ according to HIV
status. Among adults from South Africa, HBV/HIV coinfected patients had lower CD4+ T
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cell counts compared to those with HIV-monoinfection (p = 0.02), but this finding was not
replicated in the cohort from Botswana. Overall, these data provide a snapshot of the coin-
fection problem at the heart of the HIV/HBV co-epidemic, and are important to inform public
health policy, resource allocation, education, surveillance and clinical care.
Introduction
There has been a recent revival of political and clinical interest in the problem of infection with
Hepatitis B Virus (HBV) in sub-Saharan African populations in whom Human Immunodefi-
ciency Virus (HIV) is also frequently endemic [1, 2]. The progressive availability and success of
antiretroviral therapy (ART) has reduced opportunistic infection and malignancy in individu-
als with HIV, increasing survival and allowing the emergence of previously unrecognized
chronic liver disease [3, 4].
Furthermore, there is increasing evidence that chronic HIV/HBV coinfection is associated
with long-term morbidity and mortality that exceeds the impact of infection with either one of
these viruses alone in African populations [5–8]. This includes evidence of lower CD4+ T cell
counts in HIV/HBV coinfected individuals compared to HIV monoinfected patients [8–10].
Adding to the scale of the problem, many individuals in Africa are particularly vulnerable to
liver disease for a variety of other reasons including diet, genetics, and exposure to toxins and
other pathogens [6, 7, 11].
Despite these concerns, the burden and impact of HIV/HBV coinfection in sub-Saharan
Africa have not been well characterized. As reviewed recently [11], there are regional differ-
ences in the prevalence and severity of HIV, HBV and hepatitis delta virus (HDV) infection,
and the existing literature is generally based on small studies of disparate populations.
Although important information can be gained from studying HBV virological markers, such
as hepatitis B e-antigen (HBeAg) status, this information is not available for the majority of
studies published from African cohorts [11].
We therefore set out to characterize the prevalence and characteristics of HBV infection in a
large cohort of HIV-positive African women, and to determine the influence of HBV coinfec-
tion on CD4+ T-cell counts and HIV-specific CD8+ T-cell responses using ELISpot assays. We
drew upon a large bank of samples that have been gathered over the past decade for studies of
HIV infection, as well as adding a small control group of HIV-negative individuals.
We elected to focus on this geographic region as it represents populations at the epicentre of
the global HIV epidemic, in whom HBV also represents a substantial and emerging clinical
challenge. Our data provide a detailed picture of HBV/HIV in populations who are highly vul-
nerable to coinfection, for whom resources for screening, diagnosis and treatment are limited.
Materials and Methods
Study approach
Over the past decade, our group has produced numerous detailed studies of immune responses
to HIV in southern African adults (for examples, see references [12–17]). However, to date, the
prevalence and nature of coinfection with other chronic viruses in these cohorts has not been
described. When we recently undertook a review of the existing literature surrounding HIV/
HBV coinfection in these populations [11], we were alerted to the absence of clear data regard-
ing the prevalence and virologic characteristics of HBV in the region. We therefore set out to
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characterise the epidemiology and nature of HIV/HBV coinfection in this setting, drawing
upon our large pre-existing repository of clinical samples and laboratory data as a starting
point for further study.
Study populations and ethics statement
We performed a retrospective cross-sectional analysis of 1,022 African women, recruited from
antenatal and paediatric clinics (in the latter case, as the mothers of HIV-infected children)
between 2004 and 2013. Of these, 950 (93%) were HIV-positive, ART-naïve, recruited from
four cohorts described as a list below and also in Table 1, with reference to previous descrip-
tions in the published literature where applicable:
i. Durban HIV-positive cohort (n = 426): HIV-positive women attending antenatal clinics at
Cato Manor and Sinikithemba in Durban, South Africa [18, 19]. Ethics approval was given
by the University of KwaZulu-Natal Biomedical Research Ethics Committee (ref. E028/99).
ii. Kimberley HIV-positive cohort (n = 81): HIV-positive women recruited as mothers of chil-
dren attending paediatric HIV clinics in Kimberley, South Africa [13, 20]. Ethics approval
was given by Ethics Committee of the Faculty of Health Science, University of Free State,
Bloemfontein, South Africa (ref. ETOVS Nr 08/09).
iii. Gaborone HIV-positive cohort (n = 443): HIV-positive women recruited via the Mma
Bana Study [21], attending antenatal clinics in Gaborone, Botswana. Ethics approval was
given by the Health Research and Development Division, Ministry of Health, Gaborone
(ref. PPME-13/18/1).
In addition, we investigated a parallel group of HIV-negative women, in order to be able to
compare the characteristics of HBV in HIV-positive vs. HIV-negative groups. This group con-
sisted of HIV-negative antenatal women from the Masibambisane cohort, recruited at Prince
Mshiyeni Hospital, Durban, South Africa (n = 72). Ethics approval was given by the University
of KwaZulu-Natal Biomedical Research Ethics Committee (ref. BF 168.09).
All subjects gave written informed consent for participation.
Table 1. Prevalence and characteristics of HBV infection in 1,022 adult women from Botswana and South Africa.
Cohort Name / Location Masibambisane /
Durban
Sinikithemba and Cato
Manor / Durban
Kimberley Mma Bana /
Gaborone
Total
Country of origin South Africa South Africa South Africa Botswana South Africa
+ Botswana
Recruitment source Antenatal clinics Antenatal clinics Paediatric clinics (mothers
of HIV-infected children)
Antenatal
clinics
All cohorts
combined
HIV-status Negative Positive Positive Positive Mixed
Number of individuals 72 426 81 443 1,022
HIV viral load (RNA
copies/ml plasma)
Median n/a 30,800 33,947 16,400 23,300
IQR n/a 6,990–112,500 6,400–165,000 3,610–70,100 4,861–93,625
CD4 T cell count
(cells/mm3)
Median n/a 368 325 344 359
IQR n/a 258–532 225–478 228–1,342 253–507
Number with HBsAg (% of all
individuals)a
6 (8.3) 40 (9.4) 9 (10.8) 17 (3.8) 72 (7.0)
Number with HBeAg (% of
HBsAg+ individuals tested)a
1/6 (16.7) 12/40 (30.0) 1/4 (25.0) 2/10 (20.0) 16/60 (26.7)
Number with HDV 0/6 (0) 0/37 (0) 0/8 (0) 0/9 (0) 0/60 (0)
doi:10.1371/journal.pone.0134037.t001
HBV/HIV Coinfection in South Africa and Botswana
PLOSONE | DOI:10.1371/journal.pone.0134037 July 28, 2015 3 / 11
HIV-1 RNA load and CD4 T cell count
We quantified HIV-1 RNA from plasma using the Roche Amplicor Version 1.5 assay (Rotk-
reuz, Switzerland), and measured CD4+ T cell counts by flow cytometry. These assays were
done on location by the clinical centres recruiting the patients, using fresh plasma and cells.
Serological testing
The South African cohorts underwent testing for Hepatitis B surface antigen (HBsAg) retro-
spectively from frozen sera using the Biokit enzyme immune assay (Barcelona, Spain). For
Botswana, HBsAg results were performed in Gaborone, using the Murex HBsAg v3 (DiaSorin)
assay.
HBsAg-positive samples with sufficient volume underwent testing for HBeAg by the chemi-
lumiscence immune assays Architect (Abbott Diagnostics, Maidenhead, UK) (Durban cohorts)
and ADVIA Centaur CP (Siemens, Camberley, UK) (Gaborone and Kimberley cohorts). We
also investigated for potential HDV coinfection by screening HBsAg-positive samples for total
HDV antibody when sufficient sample volume was available, using the DIA.PRO HDV Ab
enzyme immune assay (Milan, Italy).
HBV DNA load and sequencing
HBsAg-positive/HBeAg-negative samples for which sufficient sample was available underwent
HBV DNA quantification by real-time PCR as previously described [22] (lower limit of
quantification 50 IU/mL). Samples with HBV DNA>500 IU/ml underwent population
(Sanger) sequencing of the HBV polymerase gene (amino acids 1–344) to determine genotype/
sub-genotype and presence of drug-resistance associated mutations (RAMs), as previously
described [22, 23]. HBV genotyping was initially done using the online automated subtyping
tool Oxford HBV BioAfrica (http://www.bioafrica.net/rega-genotype/html/indexhbv.html)
[24, 25]. To provide confirmation of these results and sub-genotyping, we undertook further
phylogenetic analysis using a panel of reference sequences with maximum likelihood (ML) as
implemented in PhyML 3.0 (1,000 bootstrap replicates) [26, 27].
IFN-gamma ELISpot Assays
We undertook ELISpot assays using samples from the Durban HIV-infected cohort with suffi-
cient available cells (n = 325, of whom 35 were positive for HBsAg (10.7%), and 10 were posi-
tive for HBeAg (28.6% of HBsAg-positives)). Ex vivo CD8+ T cell responses to HIV were
quantified by testing peripheral blood mononuclear cells (PBMCs) against a panel of 410 over-
lapping HIV-1 peptides spanning the entire HIV-1 proteome, as previously described [19].
Statistical analysis
Data were analysed using GraphPad Prism v.6.0f. Fisher’s Exact Test was used to compute sig-
nificance for categorical variables in 2x2 contingency tables. HIV-1 RNA viral loads and CD4
+ T cell counts in HBsAg-positive vs. HBsAg-negative subjects were compared using a Mann
Whitney U test. HBsAg seroprevalence was quoted with 95% confidence intervals (CI) calcu-
lated by the adjusted Wald test (http://www.measuringu.com/wald.htm).
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Results
HIV status
This study enrolled a total of 1,022 ART-naïve HIV-positive women from South Africa and
Botswana. HIV subtype was not determined, but based on the origin of the patients is likely to
have been C-clade in the majority [28]. In addition, we recruited 72 HIV-negative adults from
Durban. Raw data for the cohort are available as supplementary data (S1 Table).
There were no significant differences in CD4+ T cell count between different sub-cohorts
(S1 Fig; Table 1). HIV-1 RNA viral loads were higher in the South African cohorts (median
RNA VL 30,800 copies/ml and 33,947 copies/ml in Durban and Kimberley, respectively) than
in Botswana (median RNA VL 16,400 copies/ml; S1 Fig; Table 1).
HBsAg prevalence
The overall prevalence of HBsAg in the combined cohort was 72/1022 (7.0%; 95% CI 5.6–8.8%;
Table 1). Prevalence varied geographically: the lowest prevalence was in Botswana, where 17/
443 (3.8%, 95% CI 2.3–5.9%) individuals tested positive for HBsAg, in contrast to South Africa
(Durban and Kimberley cohorts), where 49/507 (9.7%, 95% CI 6.7–11.5%) were HBsAg
positive.
The prevalence of HBsAg was not significantly different between HIV-positive vs. HIV-neg-
ative sub-groups (66/950 (6.9%) vs. 6/72 (8.3%); p = 0.6, Fisher’s Exact Test). Restricting this
comparison to Durban (from where all our HIV-negative subjects were recruited), the preva-
lence of HBsAg was 40/426 (9.4%) versus 6/72 (8.3%) in HIV-positive and HIV-negative indi-
viduals respectively (p = 1.0).
Virological characteristics of HBV infection in HIV-positive adults
To characterize the HBV replicative status of HIV/HBV coinfected patients, we first screened
HBsAg-positive individuals for HBeAg. Overall, 16/60 (26.7%) HIV/HBV coinfected individu-
als were HBeAg positive (Table 1). Among 30 HBsAg-positive/HBeAg-negative individuals
from South Africa and Botswana the HBV DNA load was median 1.8 log10 IU/ml (IQR 1.6–3.7
log10 IU/ml). Of these, 9/30 (30%) had HBV DNA>2,000 IU/ml. HDV total antibody was not
detected in any of the 60 HBsAg-positive individuals tested (Table 1).
We sequenced the HBV polymerase gene from 16 individuals with detectable HBV DNA.
Of these, 15/16 did not contain HBV drug RAMs, but one specimen harboured the M204I
nucleos(t)ide analogue RAM. HBV genotypes were A for the South Africa cohort (9/14 (64%)
sub-genotype A1 and 5/14 (36%) A2) and D for the Botswana cohort (2/2 (100%) sub-geno-
type D3).
Impact of HBV co-infection on HIV-1 RNA load, CD4+ T-cell count and
HIV-specific CD8+ T-cell responses
Within our combined HIV-positive South African cohort (Durban and Kimberley), HBsAg-
positive individuals had statistically lower CD4+ T cell counts than HBsAg-negative individu-
als (303 vs. 372 cells/mm3, respectively; p = 0.02, Mann-Whitney test, Fig 1A). The median
HIV-1 RNA load was slightly higher in HBsAg-positive individuals than in HBsAg-negative
individuals in South Africa although this did not reach statistical significance (34,221 RNA
copies/ml vs. 29,400 copies/ml; p = 0.13, MannWhitney test; Fig 1B). No significant associa-
tion was observed between HBV status and CD4+ T cell count or HIV-1 RNA load in
Botswana (Fig 1C and 1D).
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As CD8+ T cell responses are well recognized to be an important mediator of HIV disease
control [19, 29, 30], we sought evidence of any impact of HBV coinfection on ex vivo CD8+
T cell responses to HIV using IFN-gamma ELISpot assays for 325 subjects from within the
Fig 1. Relationship between HBV status andmarkers of HIV disease in HIV-positive women from South Africa and Botswana. Panels (A) and (B):
South Africa (Durban + Kimberley cohorts pooled); Panels (C) and (D): Botswana (Gaborone). Left-hand column (panels (A) and (C)) shows CD4+ T cell
counts; right-hand column (panels (B) and (D)) shows HIV-1 RNA viral load. In each case, box represents median and 25/75th centiles, whiskers 5-95th
centiles. P values by MannWhitney U test.
doi:10.1371/journal.pone.0134037.g001
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Durban cohort. There was no significant difference in the breadth, magnitude, or protein-
specificity of IFN-gamma responses to HIV in the presence or absence of HBsAg or HBeAg
(S2 Fig).
Discussion
The virological expression of HBV infection varies substantially among HIV-positive individu-
als in sub-Saharan Africa, and its determinants remain poorly characterized [22]. This study
determined the prevalence and virological expression of HBV coinfection in a composite
cohort of ART-naïve HIV-positive adult women from South Africa and Botswana. Comparing
our HBsAg prevalence data to other published literature is difficult, as data are relatively sparse
and epidemiology varies by setting. However, broadly speaking, our current results are compa-
rable to those assimilated from the review we have recently undertaken of this region [11]; the
latter incorporated data on 11,346 HIV-positive individuals from southern Africa, of whom
687 (6.1%) were reported to have chronic HBV (median 6.0% across all studies). This study
suggests that HDV is unlikely to be a major contributory factor to chronic liver disease in the
specific settings we have studied, but further detailed work is needed to establish HDV hotspots
and risk factors.
Interestingly, although CD4+ T cell counts were comparable between our geographically
distinct sub-cohorts, plasma HIV-1 RNA levels were significantly lower in Botswana than
South Africa, likely as a result of multiple influences that include the maturity of the epidemic
and fitness of the viral infecting strain [17].
Our data point to a potential association between HBsAg-positivity and lower CD4+ T cell
counts (Fig 1A), but this is a weak effect that does not appear consistent across locations; this is
in keeping with uncertainty in the published literature to date [11]. Where this effect does oper-
ate, the direction of causality is uncertain; it is possible that chronic HBV infection may con-
tribute to the decline of CD4+ T cell populations that are already diminished by HIV, but
alternatively the effect could be explained by an increased risk of acquisition or reactivation of
chronic HBV infection in HIV-positive individuals with low CD4+ T cell counts. Without indi-
vidual level data, (e.g. duration of HIV infection), we are unable to draw any certain conclu-
sions about the factors underpinning differences in CD4+ T cell counts between cohorts or by
HBV status.
There are several caveats and limitations to our analysis. Due to the cross-sectional nature
of the study, we were unable to verify the persistence of HBsAg over time; but for the purposes
of this study we made the assumption that HBsAg-positivity represented chronic infection. It
should be noted that we enrolled women attending antenatal clinics, and that pregnancy may
modulate the nature of the immune response to viral infection; for example, it is recognized
that HBV viral loads are typically higher in the second half of pregnancy. Although HIV-posi-
tive patients were all recorded as ‘ART-naïve’ at the time of enrollment, we cannot exclude the
possibility that a minority of individuals may have accessed short courses of treatment prior to
the study. Thus the detection of the M204I substitution may reflect either transmission of a
RAM, or prior lamivudine exposure that was unreported by the patient.
It is evident that HIV/HBV coinfection patterns differ substantially by region [11], and
an attempt to combine analysis of individuals from disparate settings could be misleading.
Detailed demographic data were not recorded for these cohorts at the time of recruitment, so
we are not able to draw conclusions regarding the specific relationship of our findings to differ-
ent communities, regions and countries, or to age or socio-demographic characteristics.
To make the analysis as broad and far-reaching as possible, we avoided limiting ourselves
to a single geographic cohort. In the interests of optimizing numbers, we have pursued the
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multi-centre approach, but to emphasise differences by region we have presented epidemiology
data as separate results for individual sub-cohorts by region (Table 1; Fig 1; S1 Fig). Although
we made every effort to optimize numbers, analysis of even greater numbers of subjects would
be beneficial to form more robust conclusions.
Another influence on the epidemiology of this co-epidemic is the roll-out of the prophylac-
tic HBV vaccination that has been variably introduced across sub-Saharan Africa in the past
two decades; HBV prevalence will doubtless continue to change in accordance with the success
of this vaccine campaign [31]. A recent review from South Africa points out that although vac-
cine coverage among children has increased since the mid 1990’s, there has been no ‘catch-up’
campaign, and vulnerable individuals remain unimmunized [32]. Other countries in the region
have been slower to introduce routine vaccination [33, 34], and the coverage of vaccine cam-
paigns is uncertain. Furthermore, because we did not test for serological markers of immunity
(HBsAb or HBcAb) it is uncertain to what extent the HBsAg-negative individuals here may
have acquired vaccine-mediated or natural immunity.
The difficulty of assimilating robust and representative data on the characteristics of HIV/
HBV co-infection in this region is highlighted by this study; despite assimilating>1000 indi-
viduals over a ten year period, we identified only 72 with HBsAg-positive status. Furthermore,
our dataset is incomplete, as small volumes within some of the samples meant that we were
able to test only a subset of the whole cohort for HBeAg and HDV. There is no single system-
atic bias that we can identify that is likely to be clearly associated with this issue, but we are
unable to categorically state the influence of missing data. We were also limited by availability
of cells for ex vivo T cell studies: it remains possible that HBV-specific CD8+ T cell responses
are abrogated by the presence of HIV, but we unfortunately did not have sufficient cells to
investigate this possibility.
Despite these caveats and limitations, we believe this dataset to be of utility and importance
in providing insight into the extent and characteristics of the HBV/HIV co-epidemic in certain
southern African populations. Ongoing efforts are needed to secure prompt diagnosis and
appropriate monitoring and treatment for coinfected individuals, in order to avert an emerging
crisis of chronic liver disease.
Supporting Information
S1 Fig. Laboratory characteristics of HIV infection in adult women from three different
HIV-1 infected cohorts. (A) HIV-1 RNA viral load and (B) CD4+ T cell count. Boxes show
25–75% centiles, whiskers show 5–95% CI. There was significant variation in HIV-1 RNA viral
load between cohorts (p = 0.0002, Kruskal-Wallis test), but not in CD4+ T cell counts (ns = not
significant).
(TIFF)
S2 Fig. Relationship between HBsAg and HBeAg status and IFN-gamma ELISpot
responses to HIV proteins in a cohort of 325 HIV-infected adult women from Durban,
South Africa. (A): Total number of ELISpot responses across the entire HIV proteome
according to HBsAg status; (B): Total number of HIV proteins targeted by ELISpot responses
according to HBsAg status; (C): Number of Gag-specific ELISpot responses according to
HBsAg status; (D): Magnitude of immunodominant ELISpot response according to HBsAg sta-
tus; (E): Total number of ELISpot responses across the entire HIV proteome according to
HBeAg status; (F): Total number of HIV proteins targeted by ELISpot responses according to
HBeAg status; (G): Number of Gag-specific ELISpot responses according to HBeAg status;
(H): Magnitude of immunodominant ELISpot response according to HBeAg status. Error bars
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show 95% CI. P-values by MannWhitney U test.
(TIFF)
S1 Table. Spreadsheet containing raw data for 1,022 southern African women (tab 1), and
for the subset of 72 women testing HBsAg-positive (tab 2). Tab 1 contains cohort location,
HIV status, HBsAg status, HIV-1 RNA viral load (copies / ml plasma) and CD4+ T cell count
(cells/mm3). Tab 2 contains HBeAg status, HDV antibody status, HBV DNA viral load (IU/
ml) and HBV genotype.
(XLSX)
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